Axogen Inc vs Visa Inc — how do they compare? Axogen Inc trades at $39.35 (market cap $2.06B), while Visa Inc trades at $357.08 (market cap $677.06B). The key difference: Visa Inc is far larger — about 328.7× Axogen Inc's market cap, and Visa Inc pays a 0.75% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AXGN | V | |
|---|---|---|
Market Cap | $2.06B | $677.06B |
Sector | Technology | Financials |
52-Week High | $46.19 | $362.13 |
52-Week Low | $11.28 | $295.52 |
Enterprise Value | $1.98B | $687.65B |
Volume | — | 10,431,336 |
Dividend Yield | — | 0.75% |
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $39.49, down 2.69% today, with a bearish technical signal despite recent earnings volatility. The company reported mixed quarterly results with Q3 2025 beating estimates but Q1 2026 missing expectations. Strong analyst sentiment persists with 84% buy ratings and a $47.60 consensus price target, though negative profit margins and recent technical weakness create uncertainty.
The outlook remains cautiously optimistic given strong institutional support and reimbursement progress, but investors face risks from persistent losses and competitive pressures. The stock's current position near support at $39 suggests potential for recovery if upcoming Q2 earnings meet or exceed the $0.09 EPS estimate.
Visa (V) trades at $357.75, up 2.52% today, near its pivot point of $357 with bullish technical signals and strong analyst consensus. The company reported Q1 2026 EPS of $3.31, beating estimates, and maintains robust profitability with a 51.68% net income margin. Recent news highlights Visa's expansion into AI-driven commerce and stablecoin partnerships, positioning it for future growth in digital payments.
Outlook remains positive with a consensus price target of $394.50, implying 10% upside, supported by earnings momentum and innovation in payment technology. Risks include competitive pressures from fintech and regulatory scrutiny, but institutional holdings and a debt-to-asset ratio of 25.26% reflect financial stability. The stock offers a compelling growth profile with manageable risks for long-term investors.
Trailing returns across standard periods
Latest headlines on both assets
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →